Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cook-Waite Lidocaine with Epinephrine is an FDA-approved local anesthetic combination product marketed by Septodont under the Cook-Waite brand for dental pain management. The formulation contains lidocaine hydrochloride 2% as the active anesthetic agent combined with epinephrine (available in concentrations of 1:50,000 or 1:100,000) as a vasoconstrictor. Lidocaine works by blocking voltage-gated sodium channels to inhibit nerve conduction, while epinephrine acts on adrenergic receptors to produce local vasoconstriction, which prolongs the anesthetic effect and improves hemostasis. This small molecule combination is administered via injectable cartridges for local infiltration or nerve block techniques in routine dental procedures. The product provides rapid onset of anesthesia with a duration of approximately 60 to 90 minutes depending on the technique used.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cook-Waite Lidocaine HCl and Epinephrine.